MINISTERU TAS-SAĦĦA

MINISTRY FOR HEALTH

MALTA

Direttorat tat-Tabib Ewlieni tal-Gvern

Office of the Chief Medical Officer

DH CIRCULAR No. 455/2016
DH 3025/2016

26th December 2016

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Repaglinide Tablets

Repaglinide tablets are currently available on the Government Formulary List as 0.5mg and 2mg tablets, and can be prescribed by Consultants Endocrinology and Diabetes. Repaglinide tablets are further regulated with protocol 170 which was updated recently. Kindly refer to protocol attached.

It is being brought to your attention that for proper stock management both doses of this medication are to be used appropriately. Multiple tablets of the 0.5mg dose should not be used to replace the 2mg dose.

Your co-operation is kindly being requested to adhere to the protocol.

For your attention please.

Dr. Denis Vella Baldacchino
Chief Medical Officer

Palazzo Castellania, 15, Merchants Street, Valletta
Telephone: 00356 21224071/ 00356 22992232
Fax: 00356 22992663
Email: cmo.meh@gov.mt
Site: www.ehealth.gov.mt,

Repaglinide 0.5mg and 2mg Tablets

Prescriber Criteria: Consultant Endocrinology & Diabetes

Out-patient and In-patient use:

1. Diabetes Mellitus Type 2

Part A

Patients who are not controlled on a maximum tolerated dose of metformin (HbA1c >7% at 3 months[#]) with:

- impaired renal function with a eGFR <60ml/min *

OR

- BMI >40 **

OR

- post-prandial hyperglycaemia

Part B

Patients who are intolerant to metformin (causing withdrawal of treatment) with:

- impaired renal function with a eGFR <60ml/min *

OR

- BMI >40 **

OR

- post-prandial hyperglycaemia

[#] HbA1c blood test must be attached
* eGFR blood test must be attached
** BMI (height and weight) must be stated

Kindly note that in order for the application to be processed, when quoting the protocol number the Consultant should specify whether the patient qualifies under 'Part A' or 'Part B'.

Duration of Approval:
6 months initially
1 year thereafter